FLEXYA™
Simply flexible
FLEXYA™ was born of the experience and innovative technological vision of collaborative research: a versatile, complete and automated instrument designed for chronic patients.
Bellco, with 40 years’ experience, operates worldwide offering therapies and systems for the treatment of renal failure, multiple organ failure, sepsis and congestive heart failure with the goal of providing know-how, reliability and innovation to the scientific and medical communities.
FLEXYA™ was born of the experience and innovative technological vision of collaborative research: a versatile, complete and automated instrument designed for chronic patients.
AMPLYA™ is a multitherapeutic system for critical care. Integration of multiple extracorporeal treatments - from the more conventional to adsorption treatments - widens the therapeutic opportunities in case of organ failure.
CARPEDIEM™ was designed to offer a truly 'paediatric' device: miniature and portable, it responds to the safety and efficacy requirements for renal replacement therapies in neonatal patients.
The international dialysis population, more and more diversified and elderly, exhibits increasingly critical clinical situations due to complications and comorbidity that progressively compromise the quality of life. The challenges for Bellco’s Therapeutic Dialysis: constant research and innovation for personalised solutions. This objective can be achieved thanks to a complete range of products and systems therapy derived from the combination of advanced engineering and medical and scientific know-how.
Complex clinical conditions, such as those of patients in intensive care, undergoing surgery, with multiple traumas, sepsis, multi-organ failure, cardiopathy, affected by immune pathologies and intoxication, require integrated therapeutic approaches capable of assuring versatility, functionality, rapidity and effectiveness.
Sharing of technical and scientific skills and experience between Bellco and the most authoritative members of the medical and scientific communities lies at the heart of the continuous research and development of correct therapies.